Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with Comorbid depression: A meta-analysis of depression and cognitive outcomes

Drugs and Aging

Volumn 29, Issue 10, 2012, Pages 793-806

  Sepehry, Amir A ^a,b,c   Lee, Philip E ^a,b,c   Hsiung, Ging Yuek R ^a,b,c   Beattie, B Lynn ^a,c   Jacova, Claudia ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MEMANTINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFICACY; GERIATRIC DEPRESSION SCALE; HAMILTON SCALE; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; COGNITION; COMORBIDITY; DEPRESSION; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84874586932     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0012-5     Document Type: Review

References (74)

1. Dudgeon S. Rising tide: the impact of dementia on Canadian Society. Toronto: Alzheimer Society of Canada; 2010.
2. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nature reviews. Neurology. 2011;7(3):137-52.
3. Prince M, Bryce R, Ferri C. World Alzheimer Report 2011: the benefits of early diagnosis and intervention. London: Alzheimer's Disease International (ADI); 2011.
4. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-22. (Pubitemid 36975801)
5. Unutzer J, Katon W, Callahan CM, Williams JW Jr, Hunkeler E, Harpole L, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288(22):2836-45. (Pubitemid 35425069)
6. Clement JP, Nubukpo P. Alzheimer's disease and psychiatric disorders. Psn-Psychiatr Sci Hum Neurosci. 2008;6(2):76-81.
7. Thomas AJ, Gallagher P, Robinson LJ, Porter RJ, Young AH, Ferrier IN, et al. A comparison of neurocognitive impairment in younger and older adults with major depression. Psychol Med. 2009;39(5):725-33.
8. Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, Ware JE Jr. Detection of depressive disorder for patients receiving prepaid or fee-for-service care. Results from the Medical Outcomes Study. JAMA. 1989;262(23):3298-302. (Pubitemid 20012551)
9. Starkstein SE, Mizrahi R. Depression in Alzheimer's disease. Expert Rev Neurother. 2006;6(6):887-95. (Pubitemid 43961889)
10. Starkstein SE, Mizrahi R, Power BD. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int Rev Psychiatry. 2008;20(4):382-8.
11. Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25(2):115-26. (Pubitemid 351196123)
12. Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol. 2006;17(1):5-16. (Pubitemid 43731791)
13. Depression in primary care: detection, diagnosis, and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 1993;1(5):1-20.
14. Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias, 2nd edn. Am J Psychiatry. 2007;164(12 Suppl):5-56.
15. Hogan DB, Bailey P, Carswell A, Clarke B, Cohen C, Forbes D, et al. Management of mild to moderate Alzheimer's disease and dementia. Alzheimers Dement. 2007;3(4):355-84. (Pubitemid 47535132)
16. Dementia: The NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Leicester: National Collaborating Centre for Mental Health; 2007.
17. Kral VA. The relationship between senile dementia (Alzheimer type) and depression. Can J Psychiatry. 1983;28(4):304-6. (Pubitemid 13004759)
18. Kral VA. Depressive pseudodementia and Alzheimer's disease - a pilot study (author's transl). Der Nervenarzt. 1982;53(5):284-6. (Pubitemid 12015788)
19. Reifler BV. Diagnosing Alzheimer's disease in the presence of mixed cognitive and affective symptoms. Int Psychogeriatr. 1997;9(Suppl 1):59-64. (Pubitemid 28045340)
20. Lyons L, ElBeltagy M, Umka J, Markwick R, Startin C, Bennett G, et al. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology. 2011;215(1):105-15.
21. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):8-18.
22. Horikawa H, Kato T, Mizoguchi Y, Seki Y, Monji A, Kanba S. SSRIs inhibit interferon-gamma-induced microglial activation. Int J Neuropsychopharmacol. 2010;13(Suppl 1):75.
23. Thompson S, Herrmann N, Rapoport MJ, Lanctot KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry. 2007;52(4):248-55. (Pubitemid 46743472)
24. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
25. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis. 2nd ed. Englewood, NJ: Biostat; 2005.
26. Cooper H, Hedges LV. The handbook of research synthesis. New York: Russell Sage Foundation; 1994.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. (Pubitemid 17189972)
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. (Pubitemid 37088507)
29. Johnson BT. DSTAT: software for the meta-analytic review of research literatures. [Ver. 1.1] ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1993.
30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
31. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737-46. (Pubitemid 36818637)
32. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease Study. Am J Psychiatry. 2000;157(10):1686-9.
33. Munro CA, Brandt J, Sheppard JM, Steele CD, Samus QM, Steinberg M, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the Depression in Alzheimer's Disease Study (DIADS). Am J Geriatr Psychiatry. 2004;12(5):491-8. (Pubitemid 39181064)
34. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136-45.
35. Steinberg M, Munro CA, Samus Q, V Rabins P, Brandt J, Lyketsos CG. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. Int J Geriatr Psychiatry. 2004;19(2):144-50. (Pubitemid 38247849)
36. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18(4):332-40.
37. Magai C, Kennedy G, Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000 Winter;8(1):66-74. (Pubitemid 30036843)
38. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403-11.
39. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44. (Pubitemid 14076461)
40. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002;10(2):129-41.
41. Folstein MF, Folstein SE, McHugh PR. ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
42. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271-84. (Pubitemid 18047596)
43. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
44. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13(2):233-40. (Pubitemid 32703334)
45. Rozzini L, Chilovi BV, Conti M, Bertoletti E, Zanetti M, Trabucchi M, et al. Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. Int Psychogeriatr. 2010;22(1):114-9.
46. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86(3):638-41.
47. Stahl SM. Essential psychopharmacology: the prescriber's guide. Cambridge: Cambridge University Press; 2005.
48. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577-85.
49. Modrego PJ. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis. 2010;21(4):1077-87.
50. Belicard-Pernot C, Manckoundia P, Ponavoy E, Rouaud O, Pfitzenmeyer P. Antidepressant use in demented elderly subjects: current data. Rev Med Interne. 2009;30(11):947-54.
51. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558-67.
52. Bedard M, Squire L, Minthorn-Biggs M-B, Molloy DW, Dubois S, O'donnell M, et al. Validity of self-reports in dementia research: the Geriatric Depression Scale. Clin Gerontol. 2003;26(3):155-63. (Pubitemid 36759010)
53. Benedict RH, Brandt J. Limitation of the Mini-Mental State Examination for the detection of amnesia. J Geriatr Psychiatry Neurol. 1992;5(4):233-7.
54. Feher EP, Mahurin RK, Doody RS, Cooke N, Sims J, Pirozzolo FJ. Establishing the limits of the Mini-Mental State Examination of 'subtests'. Arch Neurol. 1992;49(1):87-92.
55. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922-35.
56. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol. 1999;56(7):857-62. (Pubitemid 29318912)
57. Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE, et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm. 2008;115(8):1213-9.
58. Mazur-Mosiewicz A, Trammell BA, Noggle CA, Dean RS. Differential diagnosis of depression and Alzheimer's disease using the Cattell-Horn-Carroll theory. Appl Neuropsychol. 2011;18(4):252-62.
59. Grant MM, Thase ME, Sweeney JA. Cognitive disturbance in outpatient depressed younger adults: evidence of modest impairment. Biol Psychiatry. 2001;50(1):35-43. (Pubitemid 32701992)
60. Rose EJ, Ebmeier KP. Pattern of impaired working memory during major depression. J Affect Disord. 2006;90(2-3):149-61. (Pubitemid 43183523)
61. Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Imbimbo BP, et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry. 2010;18(2):98-116.
62. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9.
63. Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ±2 (DIADS-2)? Int J Geriatr Psychiatry. 2011;26(6):573-83.
64. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010;22(3):346-72.
65. Sepehry AA, Lee PE, Hsiung GY, Jacova C. Stay the course: is it justified? Lancet. 2012;379(9812):220.
66. Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007;27(5):484-7. (Pubitemid 47415047)
67. Grau-Veciana JM. Treatment of non cognitive symptoms of Alzheimer's disease. Rev Neurol. 2006;42(8):482-8. (Pubitemid 47378372)
68. Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry. 2009;70(6):915-8.
69. Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol. 2012;73(5):812-20.
70. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc Nurs Ment Health Serv. 2011;49(11):13-6.
71. Strachan J, Shepherd J. Hyponatraemia associated with the use of selective serotonin re-uptake inhibitors. Aust N Z J Psychiatry. 1998;32(2):295-8. (Pubitemid 28211710)
72. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. (Pubitemid 26120810)
73. Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, et al. Design of depression in Alzheimer's disease study-2. Am J Geriatr Psychiatry. 2006;14(11):920-30. (Pubitemid 44706410)
74. Munro CA, Brandt J, Sheppard JM, Steele CD, Samus QM, Steinberg M, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry. 2004;12(5):491-8. (Pubitemid 39181064)